We wanted to determine whether the synergy we observed between EGFR- and SOS1-inhibition (Figures 3 and 4) was enhanced by SOS2 deletion in EGFR-mutated NSCLC cell lines. The gene discussed is SOS2; the disease is non-small cell lung carcinoma.